首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
【24h】

Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.

机译:辛伐他汀/羟丙基-β-环糊精包合物的制备和表征采用超临界抗溶剂(SAS)工艺。

获取原文
获取原文并翻译 | 示例
       

摘要

In the present study, the practically insoluble drug, simvastatin (SV), and its inclusion complex with hydroxypropyl beta-cyclodextrin (HP-beta-CD) prepared using supercritical antisolvent (SAS) process were investigated to improve the aqueous solubility and the dissolution rate of drug, thus enhancing its bioavailability. Inclusion complexation in aqueous solution and solid state was evaluated by the phase solubility diagram, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). The phase solubility diagram with HP-beta-CD was classified as A(L)-type at all temperatures investigated, indicating the formation of 1:1 stoichiometric inclusion complex. The apparent complexation constants (K(1:1)) calculated from phase solubility diagram were 774, 846 and 924 M(-1) at 25, 37 and 45+/-0.5 degrees C, respectively. No endothermic and characteristic diffraction peaks corresponding to SV was observed for the inclusion complex in DSC and PXRD. FT-IR study demonstrated the presence of intermolecular hydrogen bonds between SV and HP-beta-CD in inclusion complex, resulting in the formation of amorphous form. Aqueous solubility and dissolution studies indicated that the dissolution rates were remarkably increased in inclusion complex, compared with the physical mixture and drug alone. Moreover, SV/HP-beta-CD inclusion complex performed better than SV in reducing total cholesterol and triglyceride levels. This could be primarily attributed to the improved solubility and dissolution associated with inclusion complex between drug and HP-beta-CD. In conclusion, SAS process could be a useful method for the preparation of the inclusion complex of drug with HP-beta-CD and its solubility, dissolution rate and hypolipidemic activity were significantly increased by complexation between SV and HP-beta-CD.
机译:在本研究中,研究了使用超临界抗溶剂(SAS)工艺制备的几乎不溶性药物辛伐他汀(SV)及其与羟丙基β-环糊精(HP-β-CD)的包合物,以提高水溶性和溶解速度药物,从而提高其生物利用度。通过相溶解度图,差示扫描量热法(DSC),粉末X射线衍射法(PXRD),傅里叶变换红外光谱(FT-IR)和扫描电子显微镜(SEM)评估了水溶液和固态中的夹杂物络合物。在所有研究温度下,具有HP-β-CD的相溶解度图均被分类为A(L)型,表明形成了1:1化学计量的包合物。根据相溶解度图计算出的表观络合常数(K(1:1))在25、37和45 +/- 0.5摄氏度下分别为774、846和924 M(-1)。在DSC和PXRD中未观察到与SV对应的吸热和特征衍射峰。 FT-IR研究表明,包合物中SV与HP-β-CD之间存在分子间氢键,导致形成非晶形式。水溶性和溶出度研究表明,与物理混合物和单独药物相比,包合物中溶出速率显着提高。此外,SV /HP-β-CD包合物在降低总胆固醇和甘油三酸酯水平方面表现优于SV。这可能主要归因于与药物和HP-β-CD之间的包合复合物相关的溶解度和溶解度提高。总之,SAS工艺可能是制备HP-β-CD药物包合物的有用方法,并且SV与HP-β-CD的络合可以显着提高其溶解度,溶出度和降血脂活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号